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Abstract 
Objectives: Coronary angiography is regularly performed in patients with worsening signs 
and/or symptoms of heart failure (HF). However, little is known on the determinants, findings, 
and associated clinical outcomes of coronary angiography performed in patients with worsening 
heart failure.  
Methods: The BIOSTAT-CHF (A systems BIOlogy Study to TAilored Treatment in Chronic 
Heart Failure) program enrolled 2516 patients with worsening symptoms and/or signs of HF, 
either hospitalized or in the out-patient setting. All patients were included in the present 
analysis.  
Results: Of the 2516 patients included, 315 (12.5%) underwent coronary angiography within the 
30 days after the onset of worsening symptoms and/or signs of heart failure. Subjects who 
underwent angiography were more often observed as inpatients, had more often an overt acute 
coronary syndrome, had higher troponin I levels, were younger, and had better renal function 
(all p≤0.01). Patients who underwent coronary angiography had a lower risk of the primary 
outcome of death and/or HF hospitalization (adjusted HR=0.71, 95%CI=0.57-0.89; p=0.003) 
and death (adjusted HR=0.59, 95%CI=0.43-0.80, p=0.001). Among the patients who underwent 
coronary angiography, those with a coronary stenosis (39%) had a worse prognosis than those 
without stenosis (adjusted HR for the primary outcome=1.71, 95%CI=1.10-2.64, p =0.016). 
Conclusions: Coronary angiography was performed in <13% of patients with symptoms and/or 
signs of worsening heart failure. These patients were remarkably different from those that did 
not undergo coronary angiography and had a lower risk of subsequent events. The presence of 
coronary stenosis on coronary angiography was associated with a worse prognosis.  
  
Key-words: Decompensated Heart Failure; Coronary Angiography; Acute Coronary Syndrome; 
Outcomes 
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Key Messages 
What is already known about this subject? 
Coronary angiography is regularly performed in patients with worsening signs and/or symptoms 
of heart failure (HF), however previous reports show that less than 10% of these patients 
undergo coronary angiography. 
What does this study add? 
In our study 12.5% of patients underwent coronary angiography within the 30 days after the 
onset of worsening symptoms and/or signs of heart failure. Subjects who underwent 
angiography were more likely to be in-patients, more likely to have an overt acute coronary 
syndrome, had higher troponin I levels, were younger, and had better renal function. Patients 
who underwent coronary angiography had a lower risk of death and/or HF hospitalization. 
Those with a coronary stenosis had a worse prognosis than those without stenosis. 
How might this impact on clinical practice? 
These observations help inform the debate regarding the utility of coronary angiography for the 
investigation of worsening HF and might stimulate further research specifically to address this 
question. 
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Introduction 
Coronary angiography is the “reference standard” technique for the assessment of the 
presence and the extent/severity of coronary artery disease, and to define the most appropriate 
therapy1. Current heart failure guidelines state that coronary angiography is recommended for 
the determination of heart failure (HF) etiology, especially in patients who suffer from angina 
pectoris, those with a history of ventricular arrhythmia or aborted cardiac arrest, and in patients 
with intermediate to high pre-test probability of coronary artery disease, which includes a 
“positive” non-invasive stress test2, 3.   
In patients with worsening symptoms and/or signs of heart failure, coronary 
angiography may be infrequently performed, regardless of hospitalization or ambulatory status4, 
5. However, little is known about the type of patients that undergo coronary angiography, 
whether significant coronary artery disease is found, and whether it has prognostic implications.  
The aims of the present analysis are to assess: 1) related factors and characteristics of 
patients with worsening heart failure who undergo coronary angiography; 2) the findings of 
coronary angiography regarding the presence of coronary stenosis; 3) the prognostic value of 
coronary angiography and coronary stenosis. 
 
Methods 
Patient population 
BIOSTAT-CHF is a European project that enrolled 2516 HF patients from 69 centres 
in 11 European countries to determine profiles of patients with HF that do not respond to 
recommended therapies, despite anticipated up-titration. The design and first results of the study 
and patients have been described elsewhere6. In brief, patients were aged ≥18 years with 
symptoms of new-onset or worsening HF, confirmed either by a left ventricular ejection fraction 
(LVEF) of ≤40% or a BNP and/or NT-proBNP plasma levels >400 pg/ml or >2000pg/ml, 
respectively. Patients needed to be treated with either oral or intravenous furosemide ≥40 
mg/day or equivalent at the time of inclusion. Patients should not have been previously treated 
with evidence based therapies (ACEi/ARBs and β-blockers) or were receiving <50% of the 
target doses of at least one of these drugs at the time of inclusion. Initiation or up-titration of 
ACEi/ARB and/or β-blocker therapy should have been anticipated by the treating physician. 
The first three months of treatment were considered to be the optimization phase after which a 
stabilization phase of 6 months was defined. During the optimization phase, initiation or up-
titration of ACEi/ARB and/or β-blocker was performed according to the routine clinical practice 
of the treating physicians, who were encouraged to follow the ESC guidelines at the time of 
treatment7, 8. Patients with acute coronary syndrome or stroke could be included when the 
primary diagnosis for admission to hospital or outpatient clinic visit was heart failure6. The 
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recruitment period was 24 months, starting from December 2010. The last patient was included 
on December 15, 2012. Median follow-up was 21 months.  
In this post-hoc analysis, we included all coronary angiographies performed within 30 
days after the baseline visit, because coronary angiography could have been done as 
“programmed intervention” and, therefore, a time gap between the intervention and the baseline 
visit was expected. Coronary stenosis was defined as >50% luminal stenosis (Supplemental 
Table 1). Participating European countries were also divided in North and South for 
comparison, as follows: Northern Europe - Netherlands, Norway, Sweden, Germany, and UK; 
Southern Europe – France, Slovenia, Italy, Greece, Serbia, and Poland. A subanalysis by 
country was also performed.  
Ethics Board approval was obtained and all participants signed written informed 
consent before entering the study.  
Statistical analysis 
In descriptive analyses, continuous variables are expressed as mean ± standard deviation 
(SD). Categorical variables are expressed as frequencies and proportions (%). Population 
description and comparison of patients with coronary angiography vs. no coronary angiography 
performed (and coronary artery coronary stenosis vs. no stenosis) was performed using 
independent samples t-test for normally distributed continuous variables, Mann-Whitney test for 
continuous variables with a skewed distribution, and chi-square test for categorical variables. 
Normality assumptions were verified by visual inspection. No multiple imputation was 
performed.  
To determine the factors associated with having coronary angiography performed (or 
not) and to having a coronary artery coronary stenosis (or not), we developed logistic regression 
models. These models used clinical and laboratory variables with a p-value <0.1 as entry criteria 
(from Table 1). Logistic regression assumptions were checked and multicollinearity excluded. 
Linear relationship between continuous independent variables and the logit transformation of 
the dependent variable was verified by plotting the means vs. the β estimates in quintiles 
(Supplemental Figure 1). If a linear relationship was not present, then the variable was 
dichotomized at the inflexion point. Then a stepwise backward selection process was applied 
and the final model presented.  
Cox proportional hazard regression models were used to model long-term event rate 
both in univariable and multivariable analysis. Proportional hazard assumption was verified 
graphically using "log-log" plots. In the multivariable models, the covariates for adjustment 
were chosen from demographic (age and gender), clinical (previous HF hospitalization, use of 
beta-blockers and systolic blood pressure), and laboratory (NT-proBNP, blood urea nitrogen, 
hemoglobin, HDL-cholesterol, creatinine, sodium). All parameters were previously found to be 
independently associated with the outcomes in the BIOSTAT cohort and were used to build the 
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risk models derived from this cohort (URL: https://biostat-chf.shinyapps.io/calc/)9.  
The primary outcome was a composite of hospitalization for heart failure and all-cause 
death. The outcomes of HF hospitalization and death were also analyzed separately. For the 
outcome of HF hospitalization, a competing risk model (using death as competing risk) was 
used according to the method of Fine and Gray10. 
The adjudication of events (heart failure hospitalizations) were done by the treating 
physician.  
All the analysis was performed using R® software (R Core Team, 2013. R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL: http://www.R-project.org/). The competing risk models and proportional hazard 
assumption were performed using STATA (StataCorp. 2015. Stata Statistical Software: Release 
14. College Station, TX: StataCorp LP.). 
 
Results 
Characteristic of the study population 
 From the 2516 patients included in BIOSTAT-CHF, 12.5% (n=315) underwent 
coronary angiography.  
Characteristics of patients with or without coronary angiography are presented in Table 
1. Patients who underwent coronary angiography more often presented as inpatients, with an 
acute coronary syndrome (ACS), were younger, had higher heart rate, hemoglobin, estimated 
glomerular filtration rate (eGFR), alanine/aspartate aminotransferase (ALAT/ASAT) and 
troponin I levels. The troponin I threshold for coronary angiography performance was high: 
only patients in the highest troponin quintile (>36 pg/mL) were more likely to have a coronary 
angiogram performed. Supplemental Figure 1. Nonetheless, troponin I levels were linear and 
independently associated with worse prognosis in this population but added little prognostic 
information to the BIOSTAT risk models. Supplemental Table 2 and Supplemental Table 3.  
Patients who underwent coronary angiography were also more often smokers and more 
frequently treated with ACEi/ARBs, had lower LVEF, urea, and potassium, were less often 
hospitalized in the year before baseline visit, had ischemic cardiomyopathy less often 
documented, had lower proportion of atrial fibrillation, previous stroke, device therapy, and 
previous coronary intervention (p <0.01 for all). Table 1. Country subanalysis shows that the 
Netherlands and France had the higher proportion of patients undergoing coronary angiography. 
Of notice, the Netherlands contributed with more than 25% of all angiographies performed. 
Supplemental Table 4. 
Independent predictors for performing coronary angiography are presented in Table 2.  
The strongest independent predictors of undergoing coronary angiography were an in-hospital 
visit (Odds Ratio, OR =11.6, 95% Confidence Interval, CI =4.6-28.8, p <0.0001), overt acute 
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coronary syndrome (OR =3.1, 95%CI =1.9-5.0, p <0.0001), troponin I levels above 36 pg/mL 
(OR =1.6, 95%CI =1.1-2.3, p =0.011), a younger age (OR per each decade less = 1.4, 95%CI 
=1.2-1.6, p <0.0001), and better renal function (OR per 10 ml/min/1.73m2 increase in eGFR 
=1.1, 95%CI =1.0-1.2, p =0.049). Patients with a cardiac device, those with previous HF 
hospitalization and those with previous coronary intervention were less likely to have coronary 
angiography performed. Table 2. 
 
Coronary angiographic findings 
A coronary stenosis (>50% luminal stenosis) was found in 38.7% (n=122) of the 315 
patients who underwent coronary angiography. Characteristics of patients with and without a 
coronary stenosis are presented in the Supplemental Table 1. Patients with a coronary stenosis 
were older, more often male, smokers, and hypertensive, had higher proportion of pulmonary 
rales, HF of ischemic etiology more often documented, higher troponin I levels, and higher 
proportion of previous coronary intervention (p <0.01 for all).   
Among the patients who underwent coronary angiography, those with HF of ischemic 
etiology (OR =33.4, 95%CI =16.4-68.0, p <0.0001) and with higher troponin I levels (OR per 1 
log increase =1.3, 95%CI =1.0-1.7, p =0.026) were more likely to have a coronary stenosis. 
Table 3.  
 
Prognostic implications of coronary angiography and presence of coronary stenosis 
 Patients who underwent coronary angiography had a better clinical outcome compared 
to those who did not undergo coronary angiography (adjusted Hazard Ratio, HR for the primary 
composite outcome of death and/or heart failure hospitalization =0.71, 95%CI =0.57-0.89, p 
=0.003 and HR =0.59, 95%CI =0.43-0.80, p =0.001 for the outcome of death). Table 4. Among 
the patients who underwent coronary angiography, those with a coronary stenosis had worse 
prognosis (adjusted HR for the primary composite outcome of death and/or heart failure 
hospitalization =1.71, 95%CI =1.10-2.64, p =0.016 and HR =2.09, 95%CI =1.10-3.96, p =0.024 
for the outcome of death). Table 4. 
 A significant interaction between HF etiology (ischemic vs. other) and coronary 
angiography (yes vs. no) was found. Patients who underwent coronary angiography with non-
ischemic HF had a greater reduction of the primary composite outcome (HR =0.55, 95%CI 
=0.40-0.76, p <0.001) than patients who underwent coronary angiography with ischemic heart 
failure (HR =1.00, 95%CI =0.74-1.37, p =0.98; p for interaction =0.007. Figure 1 and Figure 2.  
 
Discussion 
 The present study shows that ≈13% of patients with worsening HF underwent coronary 
angiography within 30 days of presentation for worsening symptoms and/or signs of HF. In 
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general, these patients had a better clinical profile and outcome than those who did not undergo 
coronary angiography. However, patients with a coronary stenosis on coronary angiography had 
a worse prognosis compared to those without a coronary stenosis.  
 In our study, the coronary angiography rate was higher than in previous reports where 
less than 10% of the patients with worsening HF underwent coronary angiography5, 11. 
Nonetheless, in patients with decompensated HF, coronary artery disease may be the primary 
HF etiology in more than 50% of the patients12. Hence, addressing coronary artery disease as a 
therapeutic target in worsening  HF (even without overt ACS) may be associated with  
improved clinical outcome, and although a causal relation cannot be inferred, recurrent ischemic 
events are a major cause of subsequent HF decompensation and death13.  
In the present report, only 23% (n=54) of the subjects presenting with an overt ACS underwent 
coronary angiography within the worsening HF episode (±30 days). These data suggest that the 
large majority of the coronary angiographies were performed in patients with other primary 
causes for HF decompensation. Hence, in the present study physicians possibly decided to 
perform coronary angiography based on the suspicion that an underlying coronary artery disease 
was a major contributor for worsening HF signs and/or symptoms (also supported by 
particularly high troponin threshold for angiography performance). Troponin elevation is 
frequently observed in patients with decompensated HF, possibly reflecting myocardial injury 
and/or impaired myocardial perfusion, and has been associated with worse prognosis14. While 
doctors acknowledge troponin elevation as part of the decompensation episode, they may 
withhold coronary angiography unless very high troponin levels are found, because despite the 
myocardial injury, patients with decompensated HF may have a predominance of respiratory 
symptoms, high prevalence of diabetes, and use medications such as nitrates, beta-blockers, and 
ivabradine that may blunt “typical” angina pectoris symptoms15, 16. Hence, from a clinical 
standpoint it may be challenging to distinguish between a primary diagnosis of ACS with 
associated HF versus worsening HF with elevated troponin without “typical” symptoms of 
ischaemia. In selected cases, tests for myocardial viability and ischaemia and/or coronary 
angiography may help make therapeutic decisions. 
A large country variability in the performance of coronary angiography was also found, 
notably more than 25% of the angiographies were performed in the Netherlands and more than 
15% in France. These findings may reflect country variation in the accessibility to a 
catheterization laboratory. 
Diagnostic procedures may influence treatment decisions (directly and/or indirectly) 
and consequently prognosis17-19. In this context, the performance of coronary angiography may 
provide information regarding the extent/severity of coronary artery disease and also provide an 
opportunity for direct intervention (e.g., coronary revascularization) that will likely have 
influence on the follow-up, treatment and prognosis of these patients15, 20. In the present study 
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performing coronary angiography was associated with improved outcomes, finding that is 
consistent with the OPTIMIZE-HF registry11, however no causality can be established as this 
may reflect selection bias and better baseline patient profile.  In a patient-population with 
coronary artery disease and HF with reduced ejection fraction performing coronary artery 
bypass grafting (CABG) led to improved outcomes compared to medical therapy alone21.  
Whether performing more coronary angiographies in patients with decompensated HF leads to 
outcome improvement needs to be prospectively evaluated in an adequately powered trial.  
Older patients and those with worse renal function were less likely to have coronary 
angiography performed. It has been thoroughly documented that elderly patients and those with 
impaired renal function presenting with an ACS and/or acute HF undergo substantially less 
angiographic/revascularization procedures, despite deriving similar relative benefits of these 
interventions11, 22, 23. Remarkably, coronary angiography was not less likely to be performed in 
females, even though females in this study were older. Patients with cardiac devices, previous 
coronary interventions and HF hospitalization, and those observed as outpatients were less 
likely to undergo coronary angiography. These findings may be due to the assumption that the 
patients were already investigated for coronary disease at the timing of device implantation or 
that those presenting as outpatients may have less severe symptomatology and require less 
investigation. Nevertheless, these patients may be at higher risk for myocardial ischemia and 
stent restenosis24.  
We found an “interaction” between HF etiology (ischemic vs. other) and the prognostic 
value of coronary angiography. Performing a coronary angiography in patients with non-
ischemic HF was associated with a better outcome than in patients with ischemic HF. This 
finding is possibly due to the differences found in critical stenosis rates, which were much 
higher in patients with ischemic HF (>80%) and were associated with worse prognosis. Patients 
who underwent coronary angiography and had coronary stenosis documented (≈39% in the 
present cohort) had worse prognosis compared to those without coronary stenosis. The presence 
of significant coronary lesions is associated with worse prognosis, as also documented in 
previous reports25.  
 
Clinical and Research Implications 
 The present results show that coronary angiography was performed in <13% of patients 
with worsening HF. These subjects were younger and with a more favorable overall clinical 
profile. Therefore, these data should be taken as merely descriptive and no causality should be 
inferred from these observations. From a research standpoint, a trial comparing “usual care” 
versus an arm with a low threshold for coronary angiography could provide more definitive 
answers on the diagnostic and prognostic abilities of this intervention. 
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Limitations 
Several limitations should be noticed in this study. First, this is a post-hoc analysis of a 
prospective non-randomized observational study, therefore all limitations inherent to such 
analysis are applied herein, including the inability to infer causality. Additionally, it is likely 
that unmeasured variables may have accounted for the different outcomes observed. Second, the 
present study focused on changes in medication and determinants of medication up-titration 
(and not to address coronary angiography performance). Therefore, we unfortunately have no 
reliable and consistent information regarding the clinical consequences of the findings during 
coronary angiography. However, these data may reflect “real-world” practices as no guidance 
was provided with regard to coronary interventions. Third, it is also impossible to account for 
the effect of indication biases that may have determined who underwent angiography as well as 
treatment biases that may have influenced who received pharmacological therapies for coronary 
artery disease and HF. Fourth, results from stress testing and/or coronary intervention outcomes 
(e.g., stent placement, coronary artery bypass grafting referral) are not available in the dataset. 
Fifth, the participating hospitals in the BIOSTAT-CHF differed in structure (from tertiary 
university hospitals to small non-academic structures) and likely in the access to a 
catheterization laboratory, hence these findings cannot be generalized to all hospitals and HF 
patients. However, further adjustment for the type of centre did not change the strength of the 
associations. Sixth, we can only hypothesize on the reasons that led clinicians to perform a 
coronary angiogram since this information is also not available. Lastly, the data from the 
BIOSTAT-CHF come from European centres only and may not be representative of HF patients 
in other world regions.  
 
Conclusions 
Coronary angiography was performed in <13% of patients with symptoms and/or signs 
of worsening heart failure, particularly those presenting as inpatients, with an acute coronary 
syndrome, with better renal function and younger age. Performing a coronary angiogram was 
associated with improved outcomes but this observation possibly reflects a selection bias. These 
observations help inform the debate regarding the utility of coronary angiography for the 
investigation of worsening HF and might stimulate further research specifically to address this 
question. 
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Table 1. Characteristics of the BIOSTAT population by Coronary Angiography Realization  
 N Global Population 
(n=2516) 
No Coronary 
Angiography 
(n=2201) 
Coronary 
Angiography 
Performed 
(n=315) 
P-value 
Age, years 2516 68.4 ± 12.0 69.1 ± 11.9 63.7 ± 11.6 <0.0001 
Male gender, n (%) 2516 1846 (73.4 %) 1621 (73.6 %) 225 (71.4 %) 0.40 
BMI, kg/m² 2478 27.9 ± 5.5 27.8 ± 5.4 28.2 ± 6.1 0.29 
Heart rate, bpm 2497 82.3 ± 21.4 81.6 ± 21.3 87.4 ± 21.4 <0.0001 
SBP, mmHg 2511 124.7 ± 21.9 124.6 ± 21.6 125.3 ± 23.8 0.63 
DBP, mmHg 2511 74.9 ± 13.4 74.7 ± 13.0 76.1 ± 15.8 0.079 
Pulmonary rales, n (%) 2445 1291 (52.8 %) 1101 (51.5 %) 190 (61.5 %) 0.001 
Peripheral edema, n (%) 2099 1256 (59.8 %) 1106 (59.9 %) 150 (59.3 %) 0.85 
Elevated JVP, n (%) 1753 554 (31.6 %) 479 (31.2 %) 75 (34.4 %) 0.34 
NYHA class III/IV, n (%) 2446 1522 (62.2 %) 1324 (61.8 %) 198 (65.1 %) 0.26 
Orthopnea, n (%) 2511 879 (35.0 %) 745 (33.9 %) 134 (42.5 %) 0.003 
LVEF, % 2243 31.0 ± 10.6 31.4 ± 10.7 28.7 ± 9.7 <0.0001 
Northern Europe, n (%) 2516 1200 (47.7%) 1035 (47.0 %) 165 (52.4 %) 0.075 
Inpatient visit, n (%) 2516 1694 (67.3 %) 1389 (63.1 %) 305 (96.8 %) <0.0001 
Heart failure hospitalization 
within the last year, n (%) 
2516 794 (31.6 %) 
751 (34.1 %) 43 (13.7 %) <0.0001 
HF etiology: Ischemic, n (%) 2516 1103 (43.8 %) 988 (44.9 %) 115 (36.5 %) 0.005 
HF etiology: Hypertensive, n (%)  254 (10.1 %) 225 (10.2 %) 29 (9.2 %) 
 HF etiology: Valvular, n (%)  190 (7.6 %) 169 (7.7 %) 21 (6.7 %) 
 HF etiology: Other/mixed, n (%)  969 (38.5 %) 819 (37.2 %) 150 (47.6 %) 
 Precipitating factors, n (%)      
Acute coronary syndrome, n (%) 1703 155 (9.1 %) 101 (6.9 %) 54 (23.1 %) <0.0001 
Non-compliance, n (%) 1702 304 (17.9 %) 274 (18.7 %) 30 (12.9 %) 0.032 
Atrial Fibrillation, n (%) 1703 770 (45.2 %) 691 (47.0 %) 79 (33.8 %) 0.0002 
Infection, n (%) 1703 224 (13.2 %) 199 (13.5 %) 25 (10.7 %) 0.23 
Uncontrolled hypertension, n (%) 1703 244 (14.3 %) 198 (13.5 %) 46 (19.7 %) 0.012 
Renal dysfunction, n (%) 1703 439 (25.8 %) 403 (27.4 %) 36 (15.4 %) <0.0001 
Other/mixed, n (%) 1703 287 (16.9 %) 228 (15.5 %) 59 (25.2 %) 0.0002 
Coronary stenosis, n (%) 312 122 (39.1%) 0 122 (39.1 %) NA 
Hemoglobin, g/dL 2293 13.2 ± 1.9 13.1 ± 1.9 13.5 ± 1.9 0.0009 
eGFR, ml/min/1.73m2 2516 62.4 ± 23.2 61.5 ± 23.3 69.4 ± 21.7 <0.0001 
Urea, mmol/L 2083 11.4 (7.6 - 18.2) 11.8 (7.8 - 18.6) 8.9 (6.5 - 15.0) <0.0001 
Sodium, mmol/L 2327 139.1 ± 4.0 139.1 ± 4.1 139.2 ± 3.7 0.92 
Potassium, mmol/L 2324 4.3 ± 0.6 4.3 ± 0.6 4.2 ± 0.6 0.001 
Albumin, g/L 2361 32.4 ± 8.8 32.4 ± 8.9 32.2 ± 7.9 0.75 
Glucose, mmol/L 1894 7.2 ± 3.1 7.1 ± 3.1 7.3 ± 2.8 0.31 
ALAT, UI/L 1804 25.0 (17.0 - 38.0) 24.0 (16.0 - 36.0) 32.0 (21.0 - 48.5) <0.0001 
ASAT, UI/L 1598 25.0 (19.0 - 35.0) 25.0 (19.0 - 34.0) 29.0 (21.0 - 41.0) <0.0001 
Gamma-GT, UI/L 1151 55.0 (28.0 - 108.2) 55.0 (28.0 - 108.0) 56.0 (28.0 - 114.0) 0.055 
Total bilirubin, µmol/L 1381 14.0 (10.0 - 21.0) 15.0 (10.0 - 21.0) 11.6 (8.7 - 17.0) 0.43 
HDL, mmol/L 1166 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 0.32 
LDL, mmol/L 1103 2.6 ± 1.1 2.5 ± 1.0 2.8 ± 1.1 0.007 
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Total cholesterol, mmol/L 1407 4.3 ± 1.3 4.2 ± 1.3 4.5 ± 1.3 0.037 
Triglycerides, mmol/L 1309 1.5 ± 1.0 1.5 ± 1.1 1.4 ± 1.0 0.74 
LogNT-pro BNP, ng/L 2174 3.0 ± 1.4 3.1 ± 1.4 2.9 ± 1.2 0.10 
Troponin I, pg/mL 2352 12.8 (6.8 - 27.9) 12.3 (6.7 - 25.6) 19.1 (8.1 - 36.0) <0.0001 
Hypertension, n (%) 2516 1569 (62.4 %) 1381 (62.7 %) 188 (59.7 %) 0.29 
Atrial Fibrillation, n (%) 2516 1143 (45.4 %) 1044 (47.4 %) 99 (31.4 %) <0.0001 
Diabetes mellitus, n (%) 2516 819 (32.6 %) 717 (32.6 %) 102 (32.4 %) 0.94 
Never smoked, n (%) 2513 940 (37.4 %) 838 (38.1 %) 102 (32.5 %) <0.0001 
Past smoker, n (%)  1220 (48.5 %) 1083 (49.2 %) 137 (43.6 %) 
 Current smoker, n (%)  353 (14.0 %) 278 (12.6 %) 75 (23.9 %) 
 COPD, n (%) 2516    436 (17.3 %) 385 (17.5 %) 51 (16.2 %) 0.57 
Stroke, n (%) 2516 233 (9.3 %) 217 (9.9 %) 16 (5.1 %) 0.006 
Peripheral Artery Disease, n (%) 2516 273 (10.9 %) 245 (11.1 %) 28 (8.9 %) 0.23 
Device therapy, n (%) 2516 618 (24.6 %) 591 (26.9 %) 27 (8.6 %) <0.0001 
PCI or CABG, n (%) 2516 842 (33.5 %) 774 (35.2 %) 68 (21.6 %) <0.0001 
Loop diuretic, n (%) 2516 2504 (99.5 %) 2193 (99.6 %) 311 (98.7 %) 0.081 
ACEi/ARB, n (%) 2516 1820 (72.3 %) 1574 (71.5 %) 246 (78.1 %) 0.015 
Beta-blocker, n (%) 2516 2093 (83.2 %) 1829 (83.1 %) 264 (83.8 %) 0.75 
MRA, n (%) 2516 1339 (53.2 %) 1178 (53.5 %) 161 (51.1 %) 0.42 
Digoxin, n (%) 2516 491 (19.5 %) 441 (20.0 %) 50 (15.9 %) 0.081 
Death or heart failure 
hospitalization, n (%) 2516 1017 (40.4 %) 932 (42.3 %) 85 (27.0 %) <0.0001 
Death, n (%) 2516 657 (26.1 %) 612 (27.8 %) 45 (14.3 %) <0.0001 
Heart failure hospitalization n (%) 2516 609 (24.2 %) 559 (25.4 %) 50 (15.9 %) 0.0002 
Legend: MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; JVP, 
jugular venous pressure; NYHA, New York Heart Association; H, hospitalization; HF, heart 
failure; eGFR, estimated glomerular filtration rate; ALAT/ASAT, alanine and aspartate 
aminotransferase levels; NT-pro BNP, n-terminal pro brain natriuretic peptide; COPD, chronic 
pulmonary obstructive disease; PCI or CABG, percutaneous coronary intervention or coronary 
artery bypass grafting; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker. 
European regions were divided in Southern countries (Greece, Italy, Serbia, Slovenia, and 
France) vs. Northern countries (Netherlands, Sweden, Norway, Germany, Poland, and United 
Kingdom).  
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Table 2. Logistic regression for the odds of performing a coronary angiography 
Variable Odds Ratio (95%CI) for 
Coronary Angiography 
Realization 
P-value 
Inpatient visit (yes) 11.554 (4.636-28.794) <0.0001 
Acute coronary syndrome (yes) 3.117 (1.939-5.009) <0.0001 
Troponin I (>36 pg/mL) 1.603 (1.115-2.305) 0.011 
Age (per each decade less) 1.389 (1.202-1.605) <0.0001 
eGFR (per 10 ml/min/1.73m2 increase) 1.085 (1.000-1.177) 0.049 
Device Therapy (yes) 0.430 (0.254-0.727) 0.002 
Heart failure hospitalization within the last year (yes) 0.577 (0.371-0.897) 0.014 
Previous PCI or CABG (yes) 0.614 (0.413-0.912) 0.016 
Legend: CI, confidence interval; eGFR, estimated glomerular filtration rate; PCI or CABG, 
percutaneous coronary intervention or coronary artery bypass grafting. 
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Table 3. Logistic regression for the odds of having a coronary artery stenosis 
Variable Odds Ratio (95%CI) for Coronary 
Critical Stenosis 
P-value 
Ischemic Heart Failure (yes) 33.426 (16.439-67.967) <0.0001 
Troponin I (per 1 Log increase) 1.309 (1.032-1.661) 0.026 
Legend: CI, confidence interval. 
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Table 4. Prognostic assessment of coronary angiography and presence of critical stenosis 
Outcome Coronary angiography: unadjusted 
HR (95%CI)  
P-value Coronary angiography:  adjusted* 
HR (95%CI)  
P-value 
Death or HHF 0.568 (0.455-0.709) <0.0001 0.714 (0.571-0.893) ** 0.003 
HHF 0.587 (0.437-0.787) <0.0001 0.730 (0.541-0.984) 0.039 
Death 0.460 (0.340-0.623) <0.0001 0.586 (0.433-0.795) ** 0.001 
Outcome Coronary stenosis: unadjusted 
HR (95%CI)  
P-value Coronary stenosis:  adjusted* 
HR (95%CI)  
P-value 
Death or HHF 1.940 (1.261-2.985) 0.003 1.705 (1.103-2.635) 0.016 
HHF 1.463 (0.836-2.560) 0.182 1.358 (0.771-2.390) 0.289 
Death 2.716 (1.473-5.009) 0.001 2.089 (1.103-3.957) 0.024 
Legend: HR, hazard ratio; 95%CI, 95% confidence interval; HHF, hospitalization for heart 
failure. 
*model adjusted on age, gender, NT-pro BNP, hemoglobin, urea, HDL-cholesterol, serum 
sodium, serum creatinine, systolic blood pressure, use of beta-blockers, presence of peripheral 
edema, and hospitalization for heart failure in the year before inclusion – the BIOSTAT risk 
calculator (https://biostat-chf.shinyapps.io/calc/). 
P for interaction HF etiology*Coronary Angiography =0.007 for the primary outcome of death 
or HHF; P =0.004 for death; and non-significant for HHF, P =0.326. 
**HR (95%CI) results for Coronary Angiography adjusted on the above models plus Heart 
Failure Etiology (ischemic vs. other) plus the interaction between Heart Failure Etiology and 
Coronary Angiography: Death or HHF =0.553 (0.402-0.761), p <0.0001; Death =0.378 (0.235-
0.609), p <0.0001. 
Further adjustment on the type of centre: 1) university hospital, 2) large non-academic centre, 
and 3) small centre, provided overlapping results to those presented in the table.  
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Figure 1. Interplay between Heart Failure Etiology and Prognostic Value of Coronary 
Angiography for the Primary Outcome of Heart Failure Hospitalization or Death* 
 
*model adjusted on age, gender, NT-pro BNP, hemoglobin, urea, HDL-cholesterol, serum 
sodium, serum creatinine, systolic blood pressure, use of beta-blockers, presence of peripheral 
edema, and hospitalization for heart failure in the year before inclusion – the BIOSTAT risk 
calculator (https://biostat-chf.shinyapps.io/calc/). 
HF, heart failure. P for interaction between HF etiology and Coronary Angiography =0.007.
 Figure 2. Kaplan-Meier survival curves for Coronary Angiography performance according to Heart Failure etiology status 
 
Legend: CA, coronary angiography; HF, heart failure. 
